Literature DB >> 3594452

Experimental behavioral studies with oxiracetam on different types of chronic cerebral impairment.

S Banfi, L Dorigotti.   

Abstract

Oxiracetam (4-hydroxy-2-oxo-1-pyrrolidine acetamide) is a novel compound effective in improving learning and memory in normal animals as well as in animals with acute cerebral impairment induced by a variety of noxious stimuli (i.e., electroshock, neurodepressants, metabolic inhibitors, hypoxia). In accordance with a stepwise approach to the pharmacological studies, the compound was also tested in rats with chronic cerebral impairment due to aging, cerebrovascular lesions, and congenital microencephaly. To evaluate the brain telencephalic functions, the learning rate of two conditioned avoidance responses using the pole climbing test and the performance in a multiple-choice water maze were considered. Oxiracetam at doses ranging from 10 to 60 mg/kg i.p. improved the learning rate of these animals with impaired cognitive functions. The compound was active also by oral administration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3594452

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  10 in total

1.  Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices.

Authors:  A M Pugliese; R Corradetti; L Ballerini; G Pepeu
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

2.  Pilot study to determine the interaction of oxiracetam with antiepileptic drugs.

Authors:  A van Wieringen; J W Meijer; W van Emde Boas; T A Vermeij
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

Review 3.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type.

Authors:  L Parnetti; P Mecocci; A Gaiti; D Cadini; F Lombardi; M Visconti; U Senin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

5.  Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.

Authors:  L Preda; M Alberoni; S Bressi; C Cattaneo; J Parini; N Canal; M Franceschi
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 6.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

7.  Absorption and disposition of 14C-labelled oxiracetam in rat, dog and man.

Authors:  H P Gschwind; H Schütz; N Wigger; P Bentley
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

8.  Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly.

Authors:  E Perucca; J Parini; A Albrici; M Visconti; E Ferrero
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

9.  Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics.

Authors:  C Mondadori; T Ducret; A Häusler
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Mild cognitive impairment: animal models.

Authors:  Giancarlo Pepeu
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.